Jason S. Starr, DO, discusses DLL3 as a treatment target in extrapulmonary neuroendocrine carcinomas.
Jason Starr, DO
Advertisement
Articles by Jason Starr, DO
Jason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
5